Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen

Journal of Chemotherapy

Volumn 20, Issue 2, 2008, Pages 278-281

  Correale, P ^a   Fioravanti, A ^b   Bertoldi, I ^b   Montagnani, F ^a   Miracco, C ^c   Francini, Guido ^a,d  

^a Medical Oncology Section   (Italy)

^b Department of Clinical Medicine and Immunological Sciences ^*  (Italy)

^c Section of Pathology   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

Autoimmunity; Chemo immunotherapy; Colon adenocarcinoma; Discoid lupus erythematosus

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LEVOFOLINIC ACID; OXALIPLATIN;

ADULT; ANAMNESIS; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; COLON CARCINOMA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LOW DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL;

EID: 44849123867     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.2.278     Document Type: Article

References (23)

1. Correale P, Aquino A, Cusi MG, et al. Chemo-immunological therapy of colorectal carcinoma: preclinical rationale and clinical experience. Invest New Drugs 2006; 24(2):99-110.
2. Correale P, Messinese S, Caraglia M et al. A novel biweekly multi-drug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pre-treated patients with advanced colorectal carcinoma. Br J Cancer 2004; 90(9):1710-1714.
3. Correale P, Cusi MG, Del Vecchio MT, et al. Dendritic cell (DC)-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multi-drug regimen of gemcitabine, oxaliplatin, 5-fluorouracil and leucovorin (GOLF) elicits a powerful human antigen-specific CTL response with antitumour activity in vitro. J Immunol 2005; 175(2):820-828.
4. Correale P, Campoccia G, Tsang KY, et al. Recruitment of dendritic cells and enhanced antigen specific immune-reactivity in cancer patients treated with hrGM-CSF (molgramostim) and hr IL-2: results from a Phase Ib Clinical Trial. Eur J Cancer 2001; 37 (7):892-902.
5. Correale P, Cusi MG, Tsang KY, et al. Chemo-immunotherapy of metastatic colorectal carcinoma with Gemcitabine + FOLFOX 4 followed by subcutaneous (sc) Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Interleukin-2 (IL-2) induces strong immunological and antitumor activity in metastatic colon cancer patients. J Clin Oncol 2005; 23(35):8950-8958.
6. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. New Eng J Med 2006; 354:709-718.
7. Duan-Porter WD, Casciola-Rosen L, Rosen A. Autoantigens: the critical partner in initiating and propagating systemic autoimmunity. Ann N Y Acad Sci 2006; 1062:127-36.
8. Gerritsen W, Van Den Eertwegh AJ, De Gruijl TD, et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with fully human anti-CTL4 antibody (MDX-010, ipiluminab) in patients with metastatic hormone-refractory prostate cancer (MHRPC). Program Proceedings: The Prostate Cancer Symposium. 2007; 202.
9. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12(12):1005-1016.
10. Rodriguez-Lecompte JC, Kruth S, et al. Cell-based cancer gene therapy: breaking tolerance or inducing autoimmunity? Anim Health Res Rev 2004; 5(2):227-234.
11. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23(25):6043-6053.
12. Homma S, Sagawa Y, Ito M, et al. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin Exp Immunol. 2006; 144(1):41-47.
13. Riemer AB, Kurz H, Klinger M, et al. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 2005; 97(22):1663-7.
14. Quingyong JI, Gondek D, Hurwitz AA. Provision of Granulocyte Macrophage Colony stimulating factor converts an autoimmune response to a self antigen into an antitumor response. J Immunol 2005; 175:1456-1463.
15. + T cells as key regulators of immune responses. Eur J Dermatol 2003; 13: 111-116.
16. Wolf AM, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. J Immunother 2002; 25: 202-206.
17. Kukreja A, Maclaren N. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109(1):131-140.
18. + Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol 2006; 16(2):124-136.
19. + regulatory T cells in tumor immunity. Curr Top Microbiol Immunol 2005; 293:287-302.
20. + regulatory T cells. Semin Immunol 2004; 16(2):89-98.
21. Rudensky AY, Campbell DJ. In vivo sites and cellular mechanism of T reg cell-mediated suppression. J Exp Med 2006; 203 (3): 489-492.
22. Vojdani A, Erde J. Regulatory T cells, a potent immunoregulatory target for CAM researchers: the ultimate antagonist (I). Evid Based Complement Alternat Med 3(1):25-30, 2006;
23. Yoshimasu T, Nishide T, Seo N, et al. Susceptibility of T cell receptor-± chain knock-out mice to ultraviolet B light and fluorouracil: a novel model for drug-induced cutaneous lupus erythematosus. Clin Exp Immunol 2004;136: 245-254.